|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Chei-Hsiang Chen||Chairperson & Pres||N/D||N/D||N/D|
|Meng Han Xu||Mang. of the Fin. Department||N/D||N/D||N/D|
|Dr. Roger Kuo Ph.D.||Chief Operating Officer||N/D||N/D||N/D|
|Jia Wei Hong||Mang. of Accounting Department||N/D||N/D||N/D|
|Ms. Vivien Fan||Exec. VP, Spokesperson of the Admin. Center & Director||N/D||N/D||N/D|
|Mr. Bai-Feng Wu||Sr. VP of Pharmaceutical Manufacturing||N/D||N/D||N/D|
|Dr. Yan Ning Guo||COO of Pharmaceutical Bus. Center & Director||N/D||N/D||N/D|
|Qi Hua Song||Head of the Quality Assurance & Norms Office and Deputy Plant Mang.||N/D||N/D||N/D|
|Ming Yi Ba||Deputy Head of the Engineering Office||N/D||N/D||N/D|
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion. The company was founded in 2014 and is based in Hsinchu City, Taiwan.
L'ISS Governance QualityScore di UBI Pharma Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.